ArticleEuropean journal of nuclear medicine and molecular imaging2026
From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Knowledge of tumor absorbed dose (AD)–response relationships is a critical first step toward personalizing dose regimens. This study investigated these relationships at a preclinical scale and modeled the observed tumor growth by considering both cellular AD-response relationships and tumor AD distributions. Using this framework, we compared the tumor AD-response of [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE.
methodsCA20948 xenograft-bearing mice were injected with a range of activities of [177Lu]Lu-DOTATATE (1 nmol, 21.6–115.4 MBq) and [161Tb]Tb-DOTATATE (1 nmol, 17.3–91.7 MBq). The tumor doubling time was measured and correlated with individual tumor AD, determined with micro-SPECT imaging. The tumor-growth was also modeled based on cellular AD-response relationships, while considering subtumor AD distributions that were determined either with digital autoradiography or micro-SPECT.
results[161Tb]Tb-DOTATATE showed a 30% higher S-value for tumors compared to [177Lu]Lu-DOTATATE, after a correction for subcellular heterogeneity. Both treatments reached a clinically relevant tumor AD-range of 9–85 Gy and 5–87 Gy, respectively. A positive correlation was observed between the tumor doubling time and the tumor AD (p < 0.0001, R2 = 0.58), with no significant difference in AD-response between [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE (p = 0.24). The performance of the tumor-growth-model improved substantially after considering AD heterogeneity (from R2 = -64 up to R2 = 0.16).
conclusionThe tumor doubling time showed a positive correlation with the tumor AD which was largely affected by the heterogeneous AD distribution within the tumor. Findings confirm that [161Tb]Tb-DOTATATE does not increase the therapeutic efficacy compared to [177Lu]Lu-DOTATATE.
Indexed as
Identifiers
41656422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.